AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

AtaiBeckley completed enrollment in its Phase 2b Elumina trial for VLS-01, a DMT-based oral film treatment for treatment-resistant depression, with 156 patients randomized. The company plans to advance VLS-01 into Phase 3 development for major depressive disorder and generalized anxiety disorder, pending positive Phase 2 results expected in Q4 2026. VLS-01 will complement BPL-003, which is already in Phase 3 for TRD with Breakthrough Therapy Designation.